1.Castaño T, Encinas A, Pérez C, Castro A, Campillo NE, Gil C.. (2008) Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase., 16 (11):[PMID:18477512][10.1016/j.bmc.2008.04.036]
2.Salerno L, Pittalà V, Romeo G, Modica MN, Siracusa MA, Di Giacomo C, Acquaviva R, Barbagallo I, Tibullo D, Sorrenti V.. (2013) Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties., 21 (17):[PMID:23867390][10.1016/j.bmc.2013.06.040]
3.Salerno L, Pittalà V, Romeo G, Modica MN, Marrazzo A, Siracusa MA, Sorrenti V, Di Giacomo C, Vanella L, Parayath NN, Greish K.. (2015) Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines., 96 [PMID:25874340][10.1016/j.ejmech.2015.04.003]
4.Sorrenti V, Pittalà V, Romeo G, Amata E, Dichiara M, Marrazzo A, Turnaturi R, Prezzavento O, Barbagallo I, Vanella L, Rescifina A, Floresta G, Tibullo D, Di Raimondo F, Intagliata S, Salerno L.. (2018) Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines., 158 [PMID:30261468][10.1016/j.ejmech.2018.09.048]
5.Salerno L, Floresta G, Ciaffaglione V, Gentile D, Margani F, Turnaturi R, Rescifina A, Pittalà V.. (2019) Progress in the development of selective heme oxygenase-1 inhibitors and their potential therapeutic application., 167 [PMID:30784878][10.1016/j.ejmech.2019.02.027]
